. Sixtyfive percent (140 of 214) of cabozantinibtreated sufferers and 17 (19 of 109) of placebo individuals
. Sixtyfive percent (140 of 214) of cabozantinibtreated sufferers and 17 (19 of 109) of placebo sufferers had dose interruptions because of AEs. AEs have been listed as the primary…